Lobular breast carcinoma in situ
MONDO:0006270A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina. The overall lobular architecture is preserved. It is frequently multifocal (90% in some series) and bilateral. It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma.
Also known as: LCIS, lobular Ca in situ of breast, lobular Ca in situ of the breast, lobular breast carcinoma in situ, lobular carcinoma in situ, lobular carcinoma in situ (LCIS), lobular carcinoma in situ of breast, lobular carcinoma in situ of the breast
2830 clinical trials for this condition and its sub-types, 27 tagged with Lobular breast carcinoma in situ itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
One-Week radiation for breast cancer: MRI precision may cut side effects
Disease control Recruiting nowThis study tests a new radiation approach for early breast cancer that uses real-time MRI guidance to deliver just three high-dose sessions over one week, instead of the usual several weeks. The goal is to see if this shorter treatment is safe, preserves the breast's appearance, …
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New scanner could slash repeat breast cancer surgeries
Disease control Recruiting nowThis study tests a special scanner that helps surgeons see if any cancer cells are left behind during breast-conserving surgery. The goal is to remove all cancer in one go and avoid a second operation. About 100 women with invasive or in-situ breast cancer will take part. The sca…
Sponsor: University of Fribourg • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can fish oil boost Tamoxifen's power to prevent breast cancer?
Prevention Recruiting nowThis study tests whether adding high-dose omega-3 fatty acids to low-dose tamoxifen can lower breast cancer risk more than tamoxifen alone. It includes 66 overweight or obese postmenopausal women at increased risk for breast cancer. The goal is to see if the combination improves …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Aug 06, 2026 00:00 UTC
-
Could a lower tamoxifen dose prevent breast cancer in high-risk women?
Prevention Recruiting nowThis study is for premenopausal women at higher-than-average risk for breast cancer. It tests whether a low dose of tamoxifen can safely reduce breast density, which is linked to cancer risk. About 200 women will take tamoxifen, and doctors will adjust the dose if needed to get t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jul 29, 2026 00:00 UTC
-
New drug acolbifene takes on tamoxifen in breast cancer prevention trial
Prevention Recruiting nowThis study tests whether acolbifene or a low dose of tamoxifen can reduce breast cancer risk in premenopausal women at high risk. Both drugs block estrogen from reaching breast cells. Researchers will measure changes in breast tissue, blood, and mammograms over six months in 80 w…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jul 09, 2026 00:00 UTC
-
Could your diet lower breast cancer risk? new study investigates
Knowledge-focused Recruiting nowThis study follows 960 women at high risk for breast cancer to see if their diet's inflammatory potential is linked to cancer risk. Participants complete questionnaires and physical exams over time. The goal is to identify modifiable risk factors to improve prevention and early d…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC